Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q3 2025 vs. Q2 2025
How the institutions holding Cingulate Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 15 | 12 | −3 |
| Shares | 290.2K | 290.3K | +113 (0.0%) |
| Value | $1.18M | $1.14M | −$43.4K (−3.7%) |
New holders (3)
Institutions that held Cingulate Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kestra Advisory Services, LLC | 94,021 | $368.6K | 0.00% |
| Northern Trust Corp | 13,384 | $52.5K | 0.00% |
| Harbour Investments, Inc. | 2,275 | $8.92K | 0.00% |
Sold out (6)
Institutions that held Cingulate Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Commonwealth Equity Services, LLC | 120,522 | $491.0K |
| Susquehanna International Group, LLP | 33,201 | $135.1K |
| XTX Topco Ltd | 10,943 | $44.5K |
| Tower Research Capital LLC (TRC) | 1,701 | $6.92K |
| Citigroup Inc | 311 | $1.27K |
| Raymond James Financial Inc | 39 | $159 |